KPCB, DT Capital Invest In Chinese Healthcare Firm Nurotron Biotechnology

Hangzhou-based healthcare company Nurotron Biotechnology Co., Ltd. says that it has raised as much as "a hundred million RMB" ($17 million) in series C funding from Kleiner Perkins Caufield Byers (KPCB) and DT Capital Partners, according to a company announcement.

The specific amount and valuation of the investment were not disclosed.

Nurotron previously received two rounds of funding from investors include Qiming Venture Partners.

The company says that it will use the proceeds of the latest round to expand construction of industrial base for its cochlear implants.

Founded in 2006, Nurotron develops and manufactures multi-channel cochlear implant with a research & development center in California.